Summary The volume doubling time (T2) of 52 lung metastases in 21 patients was calculated from measurements done on plain chest radiographs. Follow-up times ranged from 14 to 819 days.
Measurement of the growth rate of lung metastases from both sarcomas and non-sarcomatous malignancies has for more than three decades been one of the most important sources of information on the growth characteristics of human malignancies. Sarcomas are especially well suited for this kind of studies due to their propensity for lung metastases and the often well circumscribed easily measurable lesions. Tumour doubling time measured from chest x-rays has been shown to be an important prognostic factor for overall survival in both primary and secondary lung tumours (Joseph et al., 1971; Spratt & Spratt, 1964) . In recent years the development of novel methods for the study of tumour proliferation by flow cytometry and immunohistochemistry have stimulated a renewed interest in the measurement of growth characteristics of human tumours. The most widely used method for the measurement of lung metastases in previous reports has been the graphical method on semi-logarithmic paper (Collins et al., 1956; Schwartz, 1961) . In this study, a more convenient and objective method based on linear regression is demonstrated, which may be done with an ordinary desk-top computer.
The reliability of measuremnent of tumour doubling times from chest x-rays has previously been only briefly discussed (Brenner et al., 1967) . In this study each metastasis was measured by two different investigators and the level of agreement assessed.
Materials and methods
Between 1985 and 1990, 80 patients with lung metastases from soft-tissue or skeletal sarcomas were treated by the sarcoma group at the Department of Radiotherapy and Oncology, University of Helsinki. Twenty-three of these had bi-dimensionally measurable metastases in at least two sequential chest x-rays taken at least 14 days apart. The reason for exclusion was lack of follow-up in almost all excluded case. Patients on chemotherapy were included when at least one month had elapsed since the last chemotherapy cycle. No patients received chemotherapy during the period of measurement. The metastases were measured by two independent investigators (MT and TW). Only metastases considered measurable by both investigators were included in the calculations. Metastases, which according to the Correspondence: C. Blomqvist, Department of Radiotherapy and Oncology, University of Helsinki, Haartmaninkatu 4, SF-00290 Helsinki, Finland. Received 6 January 1993; and in revised form 9 April 1993. measurements did not grow in size (nine metastases in five patients with a median area of 1.3 cm2) were excluded, which led to the exclusion of 2 patients from the study because none of the measured metastases seemed to increase in size during the follow-up period.
The final patient material consisted of 21 patients, and the total number of measured metastases was 52.
The largest longitudinal diameter (dl) and the largest transverse diameter perpendicular to this (d2) were measured from chest x-rays by the two investigators. In the measurements only PA (postero-anterior) views were utilised, since reliable measurements from lateral chest views were impossible to perform in a number of cases. In the calculations of crosssection area an elliptic shape of the metastases with an area of (n*dl*d2)/4 is postulated.
A regression analysis was performed on the logarithm of the product of the two perpendicular diameters versus time. The geometric mean of the estimates by the two investigators was used unless otherwise indicated. In patients with more than one metastasis the geometric mean of the doubling times of individual metastases was used as the patient-specific doubling time.
The statistical significance of the difference between interand intrapatient variation of tumour doubling times was studied with analysis of variance. The 95% range of agreement between the doubling time measurement by the two investigators was estimated from the standard deviation of the quotient of the two estimates under the assumption of a log-normal distribution (Brennan & Silman, 1992) . The statistical significance of investigator bias in the estimates of the doubling time was tested with the one-sample t-test on the logarithm of the quotient of the two investigators'
estimates.
The prognostic value of the doubling time for overall survival tested in a Cox analysis with the BMDP computer program (Dixon et al., 1988) .
Results
The mean age of the patients was 47 years. Nine were females. Seven patients had previously received cytotoxic '." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 68, 414-417 (Charbit, et at., 1971) . Since that only a few additional series have been published on measurement of T2 in metastases from sarcomas (Band & Kocandrle, 1975; Chaninian, 1972; R66ser, et at., 1987) . Most previous series are small, the only s;tudy larger than the present onet isz theseries of Breur et al. (Breur, 1966 In previous studies, the graphic method has been the most commonly used (Brenner et al., 1967; Collins et al., 1956; Rooser et al., 1987) . This method has the drawback of being prone to bias, since the straight lines adjoining the measurement points are estimated by eye-sight. In our study a more objective method based on linear regression analysis is used.
This method can be performed with commonly available statistical computer programs. We are aware of only one previous publication of this method in which, however, the methodology is only briefly outlined . (Charbit et al., 1971) . These figures agree very well with ours. As in previous studies the distribution of T2 was approximately log-normal (Charbit et al., 1971; Spratt, 1965; Spratt & Spratt, 1964) . The span of interpatient variation of T2 in this patient material was almost 100-fold, and an estimated 95% range of the same magnitude. The wide range of doubling times in sarcomas is probably one of the factors responsible for the large variation in the clinical behaviour of these tumours. Like previous investigators (Brenner et al., 1967; Rooser et al., 1987) we found that the variation in T2 between individual patients was considerably larger than between different metastases in the same patient. Statistical testing of this difference showed it to be highly significant, providing formal evidence for this previously reported finding.
There was a positive correlation between the logarithm of T2 and the logarithm of survival time from detection of metastases. The scatter around the regression line was, however, considerable, and the coefficient of determination (r2) was only 0.30. Thus differences in T2 explained only one third of the variation of the survival times from detection of metastatic disease. T2 has previously been found to correlate well with the prognosis in both sarcomas (Joseph et al., 1971) and lung tumours of other histology and in sarcoma patients after resection of lung metastases (Spratt & Spratt, 1964) . When tested as a prognostic factor for survival with a conventional Cox model T2 did, however, not reach statistical significance in this study, possibly because of the small sample size. Even if metastasis doubling time may be a valuable prognostic factor for outcome in metastatic lung disease its practical use is diminished by the fact that only a minority of patients (in this study one fourth) have metastases that are reliably measurable.
In animal studies it has been shown that many tumours do not grow in a constant exponential fashion, and that T2 is retarded when the tumour grows in size; this is referred to as Gompertzian growth (Laird, 1964; Laird, 1965) . In human tumours, however, no visible evidence of Gompertzian growth of lung metastases has been found by previous investigators (Brenner et al., 1967; Breur, 1966; Rooser et al., 1987; Schwartz, 1961) . Twelve patients in this study had measurements more than twice. No evidence of Gompertzian growth was found in these patients; the growth of most metastases seemed to be well described by an exponential function during the whole observation period, seen as a high linear correlation of the logarithm of metastatic area with time. The reason for the failure to detect Gompertzian growth in human tumours is unclear, but may partly be a reflection of the limited potential follow-up times in human tumours.
Little data are available on the reproducibility of measurements of growth rate of neoplastic lung lesions. Brenner has estimated the error of measurements of T2 of lung metastases to be 11% or less, assuming a follow-up time twice the tumour doubling time and measurements from six different radiographs (Brenner et al., 1967) . In a human patient material the need for early treatment precludes such a long follow-up in most cases. In this study measurements were performed by two independent investigators. The disagreement between the two estimates of T2 of individual metastases was surprisingly large. The repeatability of the patient specific T2 was better. Most of the disagreement originated from a few patients with small poorly visible metastases. Moreover, the four-to seven-fold range of disagreement in estimates is still small compared to the 100-fold variation of T2 between different patients. Interestingly one of the two investigators seemed to obtain significantly lower values of T2 than the other, even if the systematic bias was negligibly small. This, however, underscores the necessity of having all measurements done by the same investigator in repeated measurements.
